Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Restoration of correct βIVS2-654-globin mRNA splicing and HbA production by engineered U7 snRNA in β-thalassaemia/HbE erythroid cells.

Nualkaew T, Jearawiriyapaisarn N, Hongeng S, Fucharoen S, Kole R, Svasti S.

Sci Rep. 2019 May 21;9(1):7672. doi: 10.1038/s41598-019-43964-3.

2.

Formulation and chemical characterization of Clerodendrum infortunatum leaf extract in relation to anti-fungal activity.

Saha S, Mukherjee A, Biswas S, Choudhury D, Saha J, Pal S, Sarkar M, Kole RK.

Heliyon. 2018 Dec 19;4(12):e01047. doi: 10.1016/j.heliyon.2018.e01047. eCollection 2018 Dec.

3.

Simultaneous determination and risk assessment of fipronil and its metabolites in sugarcane, using GC-ECD and confirmation by GC-MS/MS.

Biswas S, Mondal R, Mukherjee A, Sarkar M, Kole RK.

Food Chem. 2019 Jan 30;272:559-567. doi: 10.1016/j.foodchem.2018.08.087. Epub 2018 Aug 21.

PMID:
30309581
4.

GC-MS/MS determination and ecological risk assessment of pesticides in aquatic system: A case study in Hooghly River basin in West Bengal, India.

Mondal R, Mukherjee A, Biswas S, Kole RK.

Chemosphere. 2018 Sep;206:217-230. doi: 10.1016/j.chemosphere.2018.04.168. Epub 2018 Apr 30.

PMID:
29751247
5.

Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients.

Preedagasamzin S, Nualkaew T, Pongrujikorn T, Jinawath N, Kole R, Fucharoen S, Jearawiriyapaisarn N, Svasti S.

Biochem Biophys Res Commun. 2018 Apr 30;499(1):86-92. doi: 10.1016/j.bbrc.2018.03.102. Epub 2018 Mar 21.

PMID:
29550480
6.

Validation of Multiresidue Method for Analysis of 31 Pesticides in Rice Using Gas Chromatography-Tandem Mass Spectrometry.

Mondal R, Kole RK, Bhttacharyya A.

J AOAC Int. 2017 Jul 1;100(4):1094-1101. doi: 10.5740/jaoacint.16-0377.

7.

Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.

Echigoya Y, Nakamura A, Nagata T, Urasawa N, Lim KRQ, Trieu N, Panesar D, Kuraoka M, Moulton HM, Saito T, Aoki Y, Iversen P, Sazani P, Kole R, Maruyama R, Partridge T, Takeda S, Yokota T.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4213-4218. doi: 10.1073/pnas.1613203114. Epub 2017 Apr 3.

8.

Validation of Multiresidue Method for Analysis of 31 Pesticides in Rice Using Gas Chromatography-Tandem Mass Spectrometry.

Mondal R, Kole RK, Bhattacharyya A.

J AOAC Int. 2017 Feb 22. doi: 10.5740/jaoacinct.16-0377. [Epub ahead of print]

PMID:
28330527
9.

Persistence of acetamiprid in paddy and soil under West Bengal agro-climatic conditions.

Saha S, Mondal R, Mukherjee S, Sarkar M, Kole RK.

Environ Monit Assess. 2017 Apr;189(4):150. doi: 10.1007/s10661-017-5871-0. Epub 2017 Mar 9.

PMID:
28281130
10.

Self-aggregating 1.8kDa polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides.

Chiper M, Tounsi N, Kole R, Kichler A, Zuber G.

J Control Release. 2017 Jan 28;246:60-70. doi: 10.1016/j.jconrel.2016.12.005. Epub 2016 Dec 9.

PMID:
27956144
11.

Comparative Evaluation of the Etching Pattern of Er,Cr:YSGG & Acid Etching on Extracted Human Teeth-An ESEM Analysis.

Issar R, Mazumdar D, Ranjan S, Krishna NK, Kole R, Singh P, Lakiang D, Jayam C.

J Clin Diagn Res. 2016 May;10(5):ZC01-5. doi: 10.7860/JCDR/2016/19739.7705. Epub 2016 May 1.

12.

Exon skipping therapy for Duchenne muscular dystrophy.

Kole R, Krieg AM.

Adv Drug Deliv Rev. 2015 Jun 29;87:104-7. doi: 10.1016/j.addr.2015.05.008. Epub 2015 May 14. Review.

PMID:
25980936
13.

Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy.

Zaharieva IT, Calissano M, Scoto M, Preston M, Cirak S, Feng L, Collins J, Kole R, Guglieri M, Straub V, Bushby K, Ferlini A, Morgan JE, Muntoni F.

PLoS One. 2013 Nov 25;8(11):e80263. doi: 10.1371/journal.pone.0080263. eCollection 2013.

14.

Oligonucleotide therapeutics in cancer.

Wan J, Bauman JA, Graziewicz MA, Sazani P, Kole R.

Cancer Treat Res. 2013;158:213-33. doi: 10.1007/978-3-642-31659-3_9.

PMID:
24222360
15.

Dissipation kinetics of tetraconazole in three types of soil and water under laboratory condition.

Alam S, Sengupta D, Kole RK, Bhattacharyya A.

Environ Monit Assess. 2013 Dec;185(12):9819-24. doi: 10.1007/s10661-013-3294-0. Epub 2013 Jun 30.

PMID:
23813125
16.

Splicing: hear and now!

Kole R.

Mol Ther. 2013 May;21(5):920-1. doi: 10.1038/mt.2013.75. No abstract available.

17.

Targeted exon skipping to address "leaky" mutations in the dystrophin gene.

Fletcher S, Adkin CF, Meloni P, Wong B, Muntoni F, Kole R, Fragall C, Greer K, Johnsen R, Wilton SD.

Mol Ther Nucleic Acids. 2012 Oct 16;1:e48. doi: 10.1038/mtna.2012.40.

18.

Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy.

Kole R, Leppert BJ.

Discov Med. 2012 Jul;14(74):59-69. Review.

19.

RNA therapeutics: beyond RNA interference and antisense oligonucleotides.

Kole R, Krainer AR, Altman S.

Nat Rev Drug Discov. 2012 Jan 20;11(2):125-40. doi: 10.1038/nrd3625. Review.

20.

Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching.

Fragall CT, Adams AM, Johnsen RD, Kole R, Fletcher S, Wilton SD.

BMC Med Genet. 2011 Oct 20;12:141. doi: 10.1186/1471-2350-12-141.

21.

Residual fate of the fungicide tetraconazole (4% EW) in mango.

Alam S, Kole RK, Bhattacharyya A.

Bull Environ Contam Toxicol. 2011 Oct;87(4):444-7. doi: 10.1007/s00128-011-0362-4. Epub 2011 Jul 27.

PMID:
21792537
22.

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.

Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJ, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F.

Lancet. 2011 Aug 13;378(9791):595-605. doi: 10.1016/S0140-6736(11)60756-3. Epub 2011 Jul 23.

23.

Modulation of RNA splicing as a potential treatment for cancer.

Bauman JA, Kole R.

Bioeng Bugs. 2011 May-Jun;2(3):125-8. Epub 2011 May 1.

24.

Anti-tumor activity of splice-switching oligonucleotides.

Bauman JA, Li SD, Yang A, Huang L, Kole R.

Nucleic Acids Res. 2010 Dec;38(22):8348-56. doi: 10.1093/nar/gkq731. Epub 2010 Aug 18.

25.

Persistence behaviour of thiamethoxam and lambda cyhalothrin in transplanted paddy.

Barik SR, Ganguly P, Kunda SK, Kole RK, Bhattacharyya A.

Bull Environ Contam Toxicol. 2010 Oct;85(4):419-22. doi: 10.1007/s00128-010-0101-2. Epub 2010 Aug 12.

PMID:
20703448
26.

Size-uniform 200 nm particles: fabrication and application to magnetofection.

Mair L, Ford K, Alam Md, Kole R, Fisher M, Superfine R.

J Biomed Nanotechnol. 2009 Apr;5(2):182-91.

27.

Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.

Goyenvalle A, Babbs A, Powell D, Kole R, Fletcher S, Wilton SD, Davies KE.

Mol Ther. 2010 Jan;18(1):198-205. doi: 10.1038/mt.2009.248. Epub 2009 Oct 20.

28.

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.

Jearawiriyapaisarn N, Moulton HM, Sazani P, Kole R, Willis MS.

Cardiovasc Res. 2010 Feb 1;85(3):444-53. doi: 10.1093/cvr/cvp335. Epub 2009 Oct 8.

29.

Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy.

Moulton HM, Wu B, Jearawiriyapaisarn N, Sazani P, Lu QL, Kole R.

Ann N Y Acad Sci. 2009 Sep;1175:55-60. doi: 10.1111/j.1749-6632.2009.04976.x.

PMID:
19796077
30.

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.

Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry C, Morgan JE, Muntoni F.

Lancet Neurol. 2009 Oct;8(10):918-28. doi: 10.1016/S1474-4422(09)70211-X. Epub 2009 Aug 25. Erratum in: Lancet Neurol. 2009 Dec;8(12):1083.

31.

Targeted correction of a thalassemia-associated beta-globin mutation induced by pseudo-complementary peptide nucleic acids.

Lonkar P, Kim KH, Kuan JY, Chin JY, Rogers FA, Knauert MP, Kole R, Nielsen PE, Glazer PM.

Nucleic Acids Res. 2009 Jun;37(11):3635-44. doi: 10.1093/nar/gkp217. Epub 2009 Apr 13.

32.

RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice.

Svasti S, Suwanmanee T, Fucharoen S, Moulton HM, Nelson MH, Maeda N, Smithies O, Kole R.

Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1205-10. doi: 10.1073/pnas.0812436106. Epub 2009 Jan 21.

33.

Therapeutic potential of splice-switching oligonucleotides.

Bauman J, Jearawiriyapaisarn N, Kole R.

Oligonucleotides. 2009 Mar;19(1):1-13. doi: 10.1089/oli.2008.0161. Review.

34.

Effect of chlorpyrifos on microbial biomass and activities in tropical clay loam soil.

Dutta M, Sardar D, Pal R, Kole RK.

Environ Monit Assess. 2010 Jan;160(1-4):385-91. doi: 10.1007/s10661-008-0702-y.

PMID:
19083110
35.

Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells.

Wan J, Sazani P, Kole R.

Int J Cancer. 2009 Feb 15;124(4):772-7. doi: 10.1002/ijc.24052.

36.

Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids.

Chin JY, Kuan JY, Lonkar PS, Krause DS, Seidman MM, Peterson KR, Nielsen PE, Kole R, Glazer PM.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13514-9. doi: 10.1073/pnas.0711793105. Epub 2008 Aug 29.

37.

An Endogenous TNF-α Antagonist Induced by Splice-switching Oligonucleotides Reduces Inflammation in Hepatitis and Arthritis Mouse Models.

Graziewicz MA, Tarrant TK, Buckley B, Roberts J, Fulton L, Hansen H, Ørum H, Kole R, Sazani P.

Mol Ther. 2008 Jul;16(7):1316-1322. doi: 10.1038/mt.2008.85. Epub 2016 Dec 8.

PMID:
28178484
38.

Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice.

Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S, Iversen PL, Kole R.

Mol Ther. 2008 Sep;16(9):1624-9. doi: 10.1038/mt.2008.120. Epub 2008 Jun 10.

39.

An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models.

Graziewicz MA, Tarrant TK, Buckley B, Roberts J, Fulton L, Hansen H, Ørum H, Kole R, Sazani P.

Mol Ther. 2008 Jul;16(7):1316-22. doi: 10.1038/mt.2008.85. Epub 2008 May 6.

40.

The importance of Bcl-xL in the survival of human RPE cells.

Zhang N, Peairs JJ, Yang P, Tyrrell J, Roberts J, Kole R, Jaffe GJ.

Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3846-53.

PMID:
17652760
41.

Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides.

Resina S, Kole R, Travo A, Lebleu B, Thierry AR.

J Gene Med. 2007 Jun;9(6):498-510.

PMID:
17471591
42.

Residual fate and persistence of endosulfan (50 WDG) in Bengal gram (Cicer arietinum).

Chowdhury AG, Das C, Kole RK, Banerjee H, Bhattacharyya A.

Environ Monit Assess. 2007 Sep;132(1-3):467-73. Epub 2006 Dec 14.

PMID:
17171238
43.

Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice.

Roberts J, Palma E, Sazani P, Ørum H, Cho M, Kole R.

Mol Ther. 2006 Oct;14(4):471-5. Epub 2006 Jul 18.

44.

Analysis of prostate-specific membrane antigen splice variants in LNCap cells.

Williams T, Kole R.

Oligonucleotides. 2006 Summer;16(2):186-95.

PMID:
16764542
45.

Impact assessment of lead on water quality of River Ganga in West Bengal, India.

Dutta S, Kole RK, Ghosh S, Nath D, Vass KK.

Bull Environ Contam Toxicol. 2005 Nov;75(5):1012-9. No abstract available.

PMID:
16400592
46.
47.

RNA modulation, repair and remodeling by splice switching oligonucleotides.

Kole R, Williams T, Cohen L.

Acta Biochim Pol. 2004;51(2):373-8. Review.

48.

Effect of pH on the persistence behavior of the insecticide buprofezin in water under laboratory conditions.

Das C, Roy S, Pal R, Kole RK, Chowdhury A.

Bull Environ Contam Toxicol. 2004 Feb;72(2):307-11. No abstract available.

PMID:
15106766
49.

Modification of alternative splicing by antisense therapeutics.

Kole R, Vacek M, Williams T.

Oligonucleotides. 2004 Spring;14(1):65-74. Review.

PMID:
15104897
50.

Effects of base modifications on antisense properties of 2'-O-methoxyethyl and PNA oligonucleotides.

Sazani P, Astriab-Fischer A, Kole R.

Antisense Nucleic Acid Drug Dev. 2003;13(3):119-28.

PMID:
12954112

Supplemental Content

Support Center